CTRI/2014/10/005146Active, not recruitingPhase 3
An Open Label Extension Trial of UT-15C SR in subjects with Pulmonary Arterial Hypertension - NA
nited Therapeutics0 sites900 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 900
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1) The subject has remained on study drug and completed all assessments during the Treatment Phase of the previous study (TDE-PH-202, TDE-PH-203, TDE-PH-205,TDE-PH-301, TDE-PH-302, or TDE-PH-308 (or other studies evaluating PAH))
- •The subject permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308) due to clinical worsening, completed premature termination assessments prior to discontinuing study drug, completed all remaining scheduled study visits AND received placebo during the Treatment Phase of the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308).
- •The subject was randomized into Dose Group 1 or Dose Group 2 in the TDE-PH-202, permanently discontinued study drug during the 12-week Treatment Phase due to clinical worsening, completed all premature termination assessments prior to discontinuing study drug and completed all remaining scheduled study visits and assessments (with the exception of the hemodynamic measurements) through Week 12. Such subjects should start treatment with UT- 15C in the open-label study at 0.25 mg BID.
- •2) The subject voluntarily gives informed consent to participate in the study.
- •3) Women of child bearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea for at least 12 consecutive months]. Sexually active women of childbearing potential must use two effective forms of contraception during the length of the study. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device (IUD), (4) partner vasectomy, or (5) abstinence. Males participating in the study must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.
Exclusion Criteria
- •1)The subject permanently discontinued study drug during the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308) due to treatment related adverse events.
- •2) The subject permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308) due to clinical worsening (as defined in those study protocols) and did not undergo premature termination assessments prior to discontinuing study drug, and/or did not complete all remaining study visits through the final scheduled visit.
- •3) The subject permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308) due to clinical worsening, completed premature termination assessments prior to discontinuing study drug, completed all remaining scheduled study visits AND received UT-15C SR during the Treatment Phase of the previous study (TDE-PH-301, TDE-PH-302, or TDE-PH-308).
- •4) The subject must not have developed any concurrent illness or condition during the conduct of the previous study, including but not restricted to, sleep apnea, chronic renal insufficiency, anemia, uncontrolled systemic hypertension or left sided heart disease, unless their physician feels that entry into this study would not be detrimental to their overall health.
Investigators
Similar Trials
Active, not recruiting
Phase 1
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-PTnited Therapeutics Corporation894
Active, not recruiting
Phase 1
An extension studyof UT-15C tablet in subjects with high blood pressure in the artery that carries blood to the lungsIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 16.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-000804-18-NLnited Therapeutics Corporation900
Active, not recruiting
Phase 1
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-FRnited Therapeutics Corporation450
Active, not recruiting
Phase 1
An extension study of UT-15C tablet in subjects with high blood pressure inthe artery that carries blood to the lungsIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use) or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or3) Collagen Vascular Disease (CVD)4) Human Immunosufficiency Virus (HIV)MedDRA version: 20.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-000804-18-ATnited Therapeutics Corporation900
Active, not recruiting
Phase 1
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTPulmonary Arterial Hypertension PAHMedDRA version: 9.1Level: LLTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-ITITED THERAPEUTICS450